Novo and Lilly compete in India as obesity drugs demand hikes
Demand for weight-loss drugs in India has shot up.
And rivals Novo Nordisk and Eli Lilly are battling for market share.
That's according to research firm Pharmarack.
It said sales of Lilly's Mounjaro, which launched in March, doubled from May to June.
Overall, it's almost hit close to 88,000 units sold - over $3 million.
:: Novo Nordisk
Meanwhile, Pharmarack said Novo sold almost 1,800 units of Wegovy since its late-June launch.
Medical journal the Lancet has said the incidence of obesity and diabetes is rising in India.
And the country ranks among the worst three globally for high obesity rates.
Pharmarack said the Indian obesity market has grown fivefold since 2021 and is valued at $73 million.
And affordability and willingness to try new drugs for obesity have propelled the growth of the market.
While Wegovy's only just launched, the active ingredient in it - semaglutide - has a two-thirds share in the Indian market, according to Pharmarack.
And Novo has sold oral versions of semaglutide for diabetes in India since 2022.
However, semaglutide will lose patent protection in India next year.
Enabling generic drugmakers to produce cheaper versions of Wegovy as India becomes a key battleground for drugmakers in the global obesity market.
Error al recuperar los datos
Inicia sesión para acceder a tu cartera de valores
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
County Durham woman who lost 16 stone warns weight loss drugs aren't the answer
A County Durham woman who lost 16 stone without drugs says she believes that slimming clubs are still needed despite the growing popularity of weight loss medication. Starting in 2010, Sue Thompson lost 16 stone over two-and-a-half years by following Slimming World's eating plan. Sue, from Chester-le-Street, now manages 145 Slimming World groups across County Durham and says that while weight loss injections such as Ozempic, Wegovy and Mounjaro have taken off as the quick solution to weight loss, lifestyle changes like those offered by her groups cannot be replaced. Sue Thompson before her weight loss (Image: SUE THOMPSON) She said: 'While, of course, I know first-hand that lasting weight loss can be achieved without drugs, I also understand that when you're desperate to lose weight, it can be tempting to try something new that promises instant results. 'I was 27 stone and 8lbs when I joined Slimming World and I used to fear that my weight would kill me, my health was impacted on a daily basis. 'The truth is though there's no magic bullet – losing weight and maintaining that weight loss requires change. Weight loss drugs need to go hand-in-hand with making changes to your diet, activity and mindset. They're not a replacement for those changes.' Sue after her wight loss. She says there is no magic bullet to losing weight (Image: SUE THOMPSON) With 64 million people in the UK overweight or living with obesity, Sue emphasised the importance of being part of a support group when trying to lose weight. She said: 'Many people join our groups after trying to lose weight beforehand, often alone and unsuccessfully. They understand they need support because it isn't easy – and it's even harder on your own. Whether you're using weight loss medication or have had surgery, lasting change needs real support. 'Members form strong friendships in groups, and there's nothing quite like the motivation and accountability that comes from losing weight with others who understand the challenges. Sue, before and after her weight loss, with her goddaughter, left, and a friend's baby, right (Image: SUE THOMPSON) 'Being part of a group helps you to stay on track and committed until the changes you're making become everyday habits.' Weight loss drugs are more accessible than ever, although a poll of 2,000 adults revealed 69 per cent of adults would still be unlikely to take them. Of those, 25 per cent said they don't want to change the way they eat, drink and socialise, and 21 per cent worried they wouldn't get the nutrition they need for good health. Most read: The 'once extinct' bird of prey now thriving in the North East after sightings Plans submitted for Grade I listed Bishop Auckland building that dates back to 1293 County Durham heritage venue earns national recognition in first year Sue credits her healthy weight loss results to community-based slimming clubs. She said: 'With Slimming World I lost weight with no deprivation or hunger and in a way that is for life. 'We will never judge anyone for going down the route of weight loss injections, we want them to know we are here with the support they need to make their weight loss sustainable.'
Yahoo
5 hours ago
- Yahoo
3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly
Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to be a dominant player in the weight loss and diabetes markets. 10 stocks we like better than Novo Nordisk › Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two phenomenal growth stocks that investors probably can't go wrong with when investing in for the long term. They are leaders in the GLP-1 weight loss space, and have been generating strong growth in recent years. But while they are similar, the stock I invested in earlier this year was Novo Nordisk. Here's why I bought it instead of its larger rival, and why I still think Novo is the better buy right now. What stands out to me about Novo Nordisk is how laser-focused it is on two crucial areas of healthcare: Diabetes and obesity. Its diabetes and obesity care segments account for the lion's share of its revenue -- 94%. It does have some revenue coming in from rare diseases, but the company's main focus is on these two areas. It has two fantastic products that are already delivering strong results in those segments: Ozempic (diabetes) and Wegovy (weight loss). Together, those two products generated sales totaling over 50 billion Danish krone ($7.9 billion) during the first three months of the year, accounting for 64% of the company's total sales. The company is working on developing more weight loss treatments, including a pill. But by simply ramping up production of its highly popular GLP-1 injections, it can still generate a lot more growth down the road. While Eli Lilly is more diversified, with oncology and immunology also being key areas of its business, I think the biggest payoff can come from focusing on diabetes and weight loss drugs. I am a bargain hunter, and with shares of Novo Nordisk crashing over the past several months, I couldn't resist the opportunity to buy the healthcare stock at what seemed like a valuation that's too good to pass up. Even today, it's trading at just 19 times its trailing earnings -- that's far below the S&P 500 average of 24. If the company's growth rate was lackluster (Novo's sales rose by 19% in the first quarter), then such a low valuation could be warranted. But that isn't the case with Novo. Even if Eli Lilly does have better-performing weight loss drugs, I don't think they are sufficiently better that they make the stock and its 63 times earnings multiple a better overall investment option. Eli Lilly can still rise in value from where it is, but I think there's far more room for Novo Nordisk to rise higher in both the short term and the long term, given its more modest price tag. Eli Lilly has been stealing the spotlight over the past year, with its products showing better results in clinical trials. In particular, Eli Lilly's Zepbound achieved superior results in a recent head-to-head trial against Wegovy (20.2% average weight loss versus 13.7%). It also didn't help that in March, Novo released stage 2 trial data for one of its more promising obesity drugs, CagriSema, which fell short of expectations. There's been a string of bad news for Novo Nordisk, which has been weighing the stock down, but there are still other drugs in the company's pipeline. With two already highly successful treatments in Wegovy and Ozempic that are approved, the company is by no means in bad shape. Plus, given that the anti-obesity market may be worth around $100 billion by 2030 (based on analyst projections), there will be plenty of room for more than just one dominant player. I also don't agree with the market that it's all about sheer weight loss. A drug needs to be well tolerated, otherwise patients may stop using it, regardless of how effective it is for losing weight or managing blood sugar levels. Ozempic was first approved in the U.S. in late 2017, so patients are going to be more familiar with its side effects than those of newer drugs. Wegovy was approved over four years ago, in 2021. Having first-mover advantages in this sense can help Novo Nordisk, as that can make its drugs default options for people who may want to try a GLP-1 treatment, but who are also concerned about the side effects. Investors appear to be underestimating the stock today. But as Novo Nordisk continues to post strong results and keeps on developing more treatments, the excitement around this once-promising business could return. That could set the stage for a big rally. Buying a stock that's crashing in value can seem like a bad idea, but it's important to consider why it's happening. If the business is in trouble and its fundamentals are broken, then it can certainly be a bad idea to take a chance on a struggling business. But that isn't the case with Novo Nordisk. It's still growing, it still has some terrific assets, and it's investing more into GLP-1 drug development. This is a situation where I believe the market has overreacted and has been both too bullish on Eli Lilly and too bearish on Novo Nordisk. When that happens, it can be an opportune time to invest in an underperforming stock like Novo Nordisk. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,764!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $980,723!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 David Jagielski has positions in Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
8 hours ago
- Yahoo
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking approval for a new and higher dose of its popular obesity medication, Wegovy (subcutaneous semaglutide 7.2 mg). Wegovy is also indicated for major adverse cardiovascular events risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. Novo Nordisk also markets semaglutide as Ozempic injection and Rybelsus oral tablet for type II diabetes (T2D). The EMA submission is backed by data from the STEP UP and STEP UP T2D studies, which evaluated semaglutide 7.2 mg in obese adult patients, with and without T2D. In the STEP UP study, the higher dose of Wegovy led to an average weight loss of 21%, with one-third of participants shedding at least 25% of their body weight compared with placebo. The 7.2 mg dose was well-tolerated and demonstrated a favorable safety profile, aligning with that of the 2.4 mg dose and previous semaglutide studies. Novo Nordisk submitted the 7.2 mg dose of Wegovy to offer a tailored option for people with obesity who need greater weight loss support. It is designed to enhance both weight reduction and related health outcomes, such as cardiovascular and kidney function, liver disease, T2D and mobility issues linked to knee osteoarthritis. Backed by a reaffirmed safety and tolerability profile, the company believes the new dose has strong potential to benefit a broader patient population, thereby expanding its reach. Novo Nordisk also plans to submit the Wegovy 7.2 mg dose for the obesity indication across several other geographies. Eli Lilly LLY is NVO's fierce competitor in the obesity space, which markets its tirzepatide medicines as Mounjaro for T2D and Zepbound for obesity. NVO's latest EMA submission for the Wegovy 7.2 mg dose is also to tackle the increasing competition from LLY's Zepbound. Lilly's Zepbound had earlier outperformed Novo Nordisk's Wegovy (20.2% compared with 13.7%, respectively) in a weight-loss head-to-head study. Despite being on the market for less than three years, Lilly's Mounjaro and Zepbound have witnessed strong sales driven by rapid demand. Several other companies, like Viking Therapeutics VKTX, are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Recently, Viking Therapeutics initiated a late-stage program (VANQUISH), comprising two phase III studies evaluating the subcutaneous version of VK2735 in obesity and T2D patients. VKTX had also initiated a mid-stage study (VENTURE) on the oral formulation of the candidate earlier this year. Year to date, Novo Nordisk shares have lost 19% compared with the industry's 1.2% decline. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below. Image Source: Zacks Investment Research Novo Nordisk is trading at a premium to the industry, as seen in the chart below. Going by the price/earnings ratio, the company's shares currently trade at 16.33 forward earnings, which is higher than 14.93 for the industry. However, the stock is trading much below its five-year mean of 29.25. Image Source: Zacks Investment Research Earnings estimates for 2025 have improved from $3.89 to $3.93 per share over the past 60 days. During the same time frame, Novo Nordisk's 2026 earnings per share estimates have decreased from $4.70 to $4.58. Image Source: Zacks Investment Research The stock's return on equity on a trailing 12-month basis is 80.95%, which is higher than 33.55% for the large drugmaker industry, as seen in the chart below. Image Source: Zacks Investment Research Novo Nordisk currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
